Log in

Relevant bibliographies by topics / Immunosuppressants such as corticosteroids / Journal articles

To see the other types of publications on this topic, follow the link: Immunosuppressants such as corticosteroids.

Journal articles on the topic 'Immunosuppressants such as corticosteroids'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Immunosuppressants such as corticosteroids.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Corticosteroids/immunosuppressants." Reactions Weekly &NA;, no. 1171 (2007): 11–12. http://dx.doi.org/10.2165/00128415-200711710-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Immunosuppressants/corticosteroids." Reactions Weekly &NA;, no. 431 (1992): 10. http://dx.doi.org/10.2165/00128415-199204310-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Corticosteroids/immunosuppressants." Reactions Weekly &NA;, no. 1213 (2008): 15. http://dx.doi.org/10.2165/00128415-200812130-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Corticosteroids/immunosuppressants." Reactions Weekly &NA;, no. 1217 (2008): 12–13. http://dx.doi.org/10.2165/00128415-200812170-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Corticosteroids/immunosuppressants/phenytoin." Reactions Weekly &NA;, no. 1174 (2007): 12–13. http://dx.doi.org/10.2165/00128415-200711740-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Corticosteroids/immunosuppressants/infliximab." Reactions Weekly &NA;, no. 1208 (2008): 11. http://dx.doi.org/10.2165/00128415-200812080-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sechrist, Samantha J., Emily Tang, Benjamin F. Arnold, and Nisha R. Acharya. "Association between immunosuppressive medications and COVID-19 hospitalisation and death: a retrospective cohort study." BMJ Open 14, no. 12 (2024): e087467. https://doi.org/10.1136/bmjopen-2024-087467.

Full text

Abstract:

ImportanceImmunocompromised status is a risk factor for severe SARS-CoV-2 infection. Little is known about how systemic corticosteroid dose and concurrent use of immunosuppressants are associated with COVID-19 outcomes.ObjectiveTo assess the association between corticosteroid dose/duration and concurrent immunosuppressant use on COVID-19 hospitalisation and death in the era of COVID-19 vaccinations.DesignThis is a retrospective cohort study using a deidentified insurance claims database from 1 July 2020 to 30 June 30, 2022, with the risk period starting on 1 July 2021. Impact of corticosteroid

APA, Harvard, Vancouver, ISO, and other styles

8

Elmahdi, Rahma, Daniel Ward, Martin T. Ernst, et al. "Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study." BMJ Open 14, no. 2 (2024): e077408. http://dx.doi.org/10.1136/bmjopen-2023-077408.

Full text

Abstract:

ObjectivePatients receiving immunosuppressives have been excluded from trials for SARS-CoV-2 vaccine efficacy. Investigation of immunosuppressants’ impact on effectiveness of vaccines, particularly in patients with immune-mediated inflammatory diseases (IMID), is therefore required.DesignWe performed a nationwide cohort study to assess the risk of COVID-19 infection in vaccinated patients with IMID exposed to immunosuppressives compared with IMID unexposed to immunosuppressives. Exposure to immunosuppressives in the 120 days before receiving the second SARS-CoV-2 mRNA vaccination was assessed.

APA, Harvard, Vancouver, ISO, and other styles

9

Lam, Stefanie, Nilufar Partovi, Lillian SL Ting, and Mary HH Ensom. "Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?" Annals of Pharmacotherapy 42, no. 7-8 (2008): 1037–47. http://dx.doi.org/10.1345/aph.1k62b.

Full text

Abstract:

Objective: To review the current clinical evidence on the effects of corticosteroid interactions with the immunosuppressive drugs cyclosporine, tacrolimus, mycophenolate, and sirotimus. Data Sources: Articles were retrieved through MEDLINE (1966–February 2008) using the terms corticosteroids, glucocorticoids, immunosuppressants, cyclosporine, tacrolimus, mycophenolate, sirolimus, drug Interactions, CYP3A4, P-glycoprotein, and UDP-glucuronosyltransferases. Bibliographies were manually searched for additional relevant articles. Study Selection and Data Extraction: All English-language studies de

APA, Harvard, Vancouver, ISO, and other styles

10

Tarhini, Ahmad A., Ni Kang, Sandra J. Lee, et al. "Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis." Journal for ImmunoTherapy of Cancer 9, no. 5 (2021): e002535. http://dx.doi.org/10.1136/jitc-2021-002535.

Full text

Abstract:

BackgroundThe impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.Patients and methodsE1609 enrolled 1673 patients with resected high-risk melanoma and evaluated adjuvant ipilimumab 3 mg/kg (ipi3) and 10 mg/kg (ipi10) versus interferon-α. We investigated the association of irAEs and of use of immunosuppressants with RFS and OS for patients treated with ipilimumab (n=1034).ResultsOccurrence of grades 1–2 irAEs was associated with RFS

APA, Harvard, Vancouver, ISO, and other styles

11

Appoo, Aria, Brandon L. Christensen, and Ranjani Somayaji. "Examining the Association between Immunosuppressants and Wound Healing: A Narrative Review." Advances in Skin & Wound Care 37, no. 5 (2024): 261–67. http://dx.doi.org/10.1097/asw.0000000000000127.

Full text

Abstract:

ABSTRACT Objective To review how different classes of immunosuppressants affect wound healing. Data Sources A literature search was conducted in PubMed, Google Scholar, and the University of Calgary Health Sciences Library. Study Selection The researchers initially screened article titles using key words such as “immunosuppressive medication,” “wound healing,” and “immunosuppression.” Articles in which the title and/or abstract contained these key words, that addressed wound healing related to immunosuppressant medications, and were published after 2000 were included in the review. When human

APA, Harvard, Vancouver, ISO, and other styles

12

Mir, Romaana, Heather May Shaw, Hariharan Kuhan, et al. "Cumulative corticosteroid exposure in patients experiencing checkpoint inhibitor toxicity." Journal of Clinical Oncology 35, no. 15_suppl (2017): e21010-e21010. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21010.

Full text

Abstract:

e21010 Background: Despite significant gains from systemic immunotherapy, prompt recognition and management of immune related adverse events (irAEs) remains key to minimising acute and chronic morbidity, and can sometimes allow treatment to be re-initiated. Active management of irAEs is corticosteroid based, with additional immunosuppressants used for steroid-refractory toxicity. Although the majority of irAEs resolve promptly, prolonged steroid exposure is required to maintain irAE control. Patients are therefore frequently exposed to cumulative high doses of steroids that in turn can be asso

APA, Harvard, Vancouver, ISO, and other styles

13

Hanly, J. G., A. Sayani, S. Doucette, S. Iczkovitz, and J. A. Ross Terres. "Treatment pathways in an inception lupus cohort over the first three years." Lupus 26, no. 2 (2016): 119–24. http://dx.doi.org/10.1177/0961203316655213.

Full text

Abstract:

Objective The treatment algorithm for new onset systemic lupus erythematosus (SLE) is less well defined than for other rheumatic diseases. We examined the treatment patterns in an inception cohort of SLE patients over the first three years of disease between 2000 and 2010. Methods Patients fulfilled the American College of Rheumatology classification criteria for SLE within 12 months of enrollment and completed three subsequent annual visits. Data collection included patient demographics, SLE manifestations, medications, SLE disease activity index-2K (SLEDAI-2K) and Systemic Lupus Internationa

APA, Harvard, Vancouver, ISO, and other styles

14

Zerhoudi, R., K. Bourzeg, H. Eljazouli, et al. "Beyond the Kidneys: Cardiac Involvement in Anca Vasculitis." Cardiology and Angiology: An International Journal 14, no. 1 (2025): 98–105. https://doi.org/10.9734/ca/2025/v14i1478.

Full text

Abstract:

Introduction: ANCA-associated vasculitis (AAV) is an autoimmune disease primarily affecting the kidneys and lungs; however, cardiac involvement, though rare, can present a significant diagnostic challenge. This complication is often underestimated and may manifest as myocarditis or heart failure, necessitating a thorough cardiological assessment. Diagnosis relies on echocardiography and advanced imaging techniques, while therapeutic management involves a combination of corticosteroids and immunosuppressants. Aim: This case report highlights the importance of rigorous cardiac monitoring in this

APA, Harvard, Vancouver, ISO, and other styles

15

Fernandez Milano, Annika, Sarah Krieg, and Karel Kostev. "Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease." Journal of Clinical Medicine 13, no. 21 (2024): 6408. http://dx.doi.org/10.3390/jcm13216408.

Full text

Abstract:

Background: Biologics are a cornerstone in the treatment of severe cases of inflammatory bowel disease (IBD) and aim to control the disease and improve quality of life. This study investigated changes in nonbiologic medication prescriptions for IBD patients initiating biologic therapy in Germany. Methods: This study used data from anonymized pharmacy records in the German longitudinal prescription (LRx) database and included biologic-naive IBD patients who received their first biologic therapy prescription between 2016 and 2022. Changes in prescription rates and pill counts for nonbiologic med

APA, Harvard, Vancouver, ISO, and other styles

16

Franeková, Janka, Marek Protuš, Eva Kieslichová, et al. "Changes in Sepsis Biomarkers after Immunosuppressant Administration in Transplant Patients." Mediators of Inflammation 2021 (January 5, 2021): 1–9. http://dx.doi.org/10.1155/2021/8831659.

Full text

Abstract:

Sepsis biomarkers change continuously during the postoperative period. We aimed to demonstrate the influence of immunosuppressants after transplantation (Tx) on presepsin, procalcitonin, CRP, white blood cells, and IL-6. A group of 140 patients after major surgery (86 non-Tx, 54 Tx) without any signs of sepsis or infectious complications was followed for 7 days. The changes in biomarkers were analyzed with respect to the type of surgery, organ, and induction immunosuppressant used (antithymocyte globulin, corticosteroids, or basiliximab/rituximab). Concentrations (95th percentiles) of presepsi

APA, Harvard, Vancouver, ISO, and other styles

17

Panaccione, Remo, A. Hillary Steinhart, Brian Bressler, et al. "Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease." Journal of the Canadian Association of Gastroenterology 2, no. 3 (2018): e1-e34. http://dx.doi.org/10.1093/jcag/gwz019.

Full text

Abstract:

Abstract Background & Aims Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then

APA, Harvard, Vancouver, ISO, and other styles

18

Hasan, Nasiq, Rohan Chawla, Nawazish Shaikh, Sindhuja Kandasamy, Shorya Vardhan Azad, and M. Dheepak Sundar. "A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology." Therapeutic Advances in Ophthalmology 14 (January 2022): 251584142210974. http://dx.doi.org/10.1177/25158414221097418.

Full text

Abstract:

Systemic immunosuppressants and biologicals have been a valuable tool in the treatment of inflammatory diseases and malignancies. The safety profile of these drugs has been debatable, especially in localized systems, such as the eye. This has led to the search for fairly local approaches, such as intravitreal, subconjunctival, and topical route of administration. Immunosuppressants have been used as a second-line drug in patients intolerable to corticosteroids or those who develop multiple recurrences on weaning corticosteroids. Similarly, biologicals have also been used as the next line of th

APA, Harvard, Vancouver, ISO, and other styles

19

Garhewal, Dr Ashwini, Dr Nidhi Bhatnagar, Dr Sangita Shah, Dr Rahul Rajvanshi, Dr Dhara Shah, and Dr Hiren Darji. "Cold Agglutinin-Induced Haemolysis in SLE Patient: A Case Series." BJKines National Journal of Basic & Applied Sciences 17, no. 01 (2025): 40–44. https://doi.org/10.56018/20250606.

Full text

Abstract:

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause hemolytic anemia, usually linked to warm antibodies. Cold agglutinin disease (CAD) in SLE is rare. This report presents three cases of severe anemia in SLE patients, emphasizing diagnosis, treatment, and the role of corticosteroids and immunosuppressants in management. Case Series: This case series presents three female patients with systemic lupus erythematosus (SLE) complicated by cold agglutinin disease. Severe anemia was confirmed with positive direct antiglobulin tests. Treatment included corti

APA, Harvard, Vancouver, ISO, and other styles

20

Iype, Madathil Shinu Mary, Akhilesh Kunoor, and Anila Kn. "A TREATMENT DILEMMA CONCERNING IMMUNOSUPPRESSANT USE: A CASE REPORT." Asian Journal of Pharmaceutical and Clinical Research 10, no. 10 (2017): 4. http://dx.doi.org/10.22159/ajpcr.2017.v10i10.18865.

Full text

Abstract:

Immunosuppressants including corticosteroids (prednisolone >15 mg/day) are responsible for an increased risk of susceptibility to infections (especially pneumonia, tuberculosis [TB] including extra pulmonary TB), an important safety concern when providing immunosuppressive therapy. Anti-TB treatment (ATT) is medicines used to treat tuberculosis, an infectious disease which can affect lungs and other organs. Isoniazid, rifampicin, and pyrazinamide are known to cause ATT induced hepatitis. The prevalence of immunosuppressant induced TB and pyrazinamide induced hepatotoxicity during treatment

APA, Harvard, Vancouver, ISO, and other styles

21

Tarhini, Ahmad A., Sandra J. Lee, Ni Kang, et al. "Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis." Journal of Clinical Oncology 38, no. 5_suppl (2020): 60. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.60.

Full text

Abstract:

60 Background: E1609 evaluated adjuvant ipilimumab at 3 mg/kg (ipi3) and 10 mg/kg (ipi10) versus high-dose interferon-α (HDI). In-depth analysis of irAEs and the use of immunosuppressants and hormone replacement may provide important lessons for management and future research. Methods: E1609 enrolled 1670 adult pts with resected cutaneous melanoma (AJCC7 IIIB, IIIC, M1a, M1b); Table. We investigated the characteristics of irAEs, corticosteroid, immunosuppressant and hormone use on the ipi arms and association with outcome. Stratified log-rank test was used and since most irAEs were observed wi

APA, Harvard, Vancouver, ISO, and other styles

22

Mittmann, Nicole, Brian Chan, Sandra Knowles, P. Régine Mydlarski, Lidia Cosentino, and Neil Shear. "Effect of Intravenous Immunoglobulin on Prednisone Dose in Patients with Pemphigus Vulgaris." Journal of Cutaneous Medicine and Surgery 10, no. 5 (2006): 222–27. http://dx.doi.org/10.2310/7750.2006.00053.

Full text

Abstract:

Background: Current therapeutic options for the treatment of pemphigus vulgaris (PV) are prednisone and immunosuppressants. Patients unresponsive to high-dose systemic corticosteroids and conventional immunosuppressants may respond to intravenous immunoglobulin (IVIG). Objective: The primary outcome was the change in prednisone dose at 6 months and 1 year post-IVIG administration. Methods: A retrospective chart review of PV patients treated at Sunnybrook and Women's College Health Sciences Centre between January 1999 and October 2004 was conducted. Demographic information, corticosteroid and I

APA, Harvard, Vancouver, ISO, and other styles

23

Sushma B , Dr. Keerthi Sashank , Dr. Dhanraj M Ganapathy. "AWARENESS OF MANAGEMENT OF ORAL SARCOIDOSIS AMONG DENTAL STUDENTS." Cuestiones de Fisioterapia 54, no. 3 (2025): 4543–55. https://doi.org/10.48047/0e0e7786.

Full text

Abstract:

Introduction: Sarcoidosis is a multi-system, chronic granulomatous disorder of unknown etiology that typically affectsyoung adults. Clinically it is found to affect the lungs, and less frequently the skin, eyes, lymph nodes, salivary glands andnervous system. Histopathologically, it is characterised by non-caseating inflammatory granuloma. Drugs of choice forsarcoidosis can be corticosteroids and for those patients who do not respond favourably to corticosteroids, alternativesteroid-sparing drugs like immunosuppressants are given.

APA, Harvard, Vancouver, ISO, and other styles

24

Nishiguchi, Mana, Yuki Yamamoto, and Masatoshi Jinnin. "Novel Disease-Modifying Drugs against Skin Fibrosis of Systemic Sclerosis." Trends in Immunotherapy 4, no. 2 (2020): 59. http://dx.doi.org/10.24294/ti.v4.i2.1050.

Full text

Abstract:

Systemic sclerosis (SSc) or scleroderma is an autoimmune disorder characterized by tissue fibrosis of the skin and internal organs. The etiology of the skin fibrosis is thought to be thickened dermis due to uncontrolled excessive deposition of various extracellular matrix, mainly type I collagen.Systemic treatments with anti-inflammatory and cytotoxic immunosuppressive properties, such as corticosteroids and immunosuppressants, are usually considered for skin sclerosis of patients with SSc. However, their approach must be initiated at the early stage, before the fibrosis is completed, and the

APA, Harvard, Vancouver, ISO, and other styles

25

Asano, Shotaro, Rie Tanaka, Hidetoshi Kawashima, and Toshikatsu Kaburaki. "Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab." Case Reports in Ophthalmology 10, no. 1 (2019): 145–52. http://dx.doi.org/10.1159/000500077.

Full text

Abstract:

Background: Adalimumab, a human anti-tumor necrosis factor-ɑ monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis. This is the first case series of adalimumab administrations for relentless placoid chorioretinitis (RPC) patients. Case Presentation: We report 2 cases of RPC where successful treatments were achieved with adalimumab. A 34-year-old woman developed conjunctival hyperemia, mild iridocyclitis, and multiple atrophic retinal lesions, along with exudative changes that were widespread from the posterior pole to peripheral

APA, Harvard, Vancouver, ISO, and other styles

26

Chapman, Roger W., Richard J. Aspinall, Palak Trivedi, Gavin Wright, and Michael Heneghan. "Challenges in the use of corticosteroids in the management of autoimmune hepatitis." Gastrointestinal Nursing 17, Sup10 (2019): S30—S36. http://dx.doi.org/10.12968/gasn.2019.17.sup10.s30.

Full text

Abstract:

Autoimmune hepatitis is widely assumed by health-care professionals to be a disease that is easily controlled through the use of corticosteroids and immunosuppressants but recent studies in the UK indicate highly variable treatment regimens and often unsatisfactory treatment outcomes, such as dependence on long-term high-dose steroids and ongoing need for liver transplantation in some cases. The therapeutic use of the systemically acting corticosteroid prednisolone results in unacceptable side effects in many patients. Recent evidence suggests that it is not always necessary to use high-dose s

APA, Harvard, Vancouver, ISO, and other styles

27

Chapman, Roger W., Richard J. Aspinall, Palak Trivedi, Gavin Wright, and Michael Heneghan. "Challenges in the use of corticosteroids in the management of autoimmune hepatitis." British Journal of Hospital Medicine 80, no. 10 (2019): 594–99. http://dx.doi.org/10.12968/hmed.2019.80.10.594.

Full text

Abstract:

Autoimmune hepatitis is widely assumed by health-care professionals to be a disease that is easily controlled through the use of corticosteroids and immunosuppressants but recent studies in the UK indicate highly variable treatment regimens and often unsatisfactory treatment outcomes, such as dependence on long-term high-dose steroids and ongoing need for liver transplantation in some cases. The therapeutic use of the systemically acting corticosteroid prednisolone results in unacceptable side effects in many patients. Recent evidence suggests that it is not always necessary to use high-dose s

APA, Harvard, Vancouver, ISO, and other styles

28

Bishnoi, Anuradha, Dipankar De, Sanjeev Handa, and Rahul Mahajan. "Biologics in autoimmune bullous diseases: Current scenario." Indian Journal of Dermatology, Venereology and Leprology 87 (July 1, 2021): 611–20. http://dx.doi.org/10.25259/ijdvl_886_19.

Full text

Abstract:

Autoimmune bullous diseases can be intraepidermal (pemphigus group of disorders) or subepidermal (pemphigoid group of disorders). The treatment of these disorders chiefly comprises corticosteroids and immunosuppressant adjuvants like azathioprine and mycophenolate mofetil. Autoantibodies are the main mediators of these diseases. Rituximab, a chimeric anti-CD20 monoclonal antibody targeting B-cells, has emerged as an excellent treatment option for refractory pemphigus vulgaris in the last decade. Since then, many new biologics have been proposed/explored for managing autoimmune bullous diseases

APA, Harvard, Vancouver, ISO, and other styles

29

Zhang, Ting, Ying Zhu, and Gezhi Xu. "Clinical Features and Treatments of Syphilitic Uveitis: A Systematic Review and Meta-Analysis." Journal of Ophthalmology 2017 (2017): 1–15. http://dx.doi.org/10.1155/2017/6594849.

Full text

Abstract:

Purpose. To investigate the clinical features and efficacies of treatments for syphilitic uveitis. Methods. PubMed was searched for studies of syphilitic uveitis published between January 1990 and October 2016. The clinical features were summarized and appraised. The pooled success rate was defined as an improved or maintained final visual acuity and was calculated with 95% confidence intervals (CIs). Heterogeneity, subgroup analysis, sensitivity analysis, and publication bias were assessed. Results. Thirty-two studies involving 670 patients were analyzed. The most common type of syphilitic uv

APA, Harvard, Vancouver, ISO, and other styles

30

Reddy, Pallavi Gaddam, and Maryam Maqsood. "Encountering steroid treatment induced tinea incognito: a case report." International Journal of Research in Dermatology 9, no. 3 (2023): 123–25. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20231165.

Full text

Abstract:

Tinea incognito refers to a type of dermatophyte infection that affects the skin, and its signs and symptoms upon presentation tend to appear permutated due to the prior use of immunosuppressants, corticosteroids or calcineurin inhibitors. We present a 42-year-old Asian (Indian) male patient with scaly erythematous rashes, mimicking annular erythema, and developing post-corticosteroid usage after an elective hair transplant procedure. The results of the biopsy reported that erythema annulare centrifugum (EAC) was absent, and the sample was suggestive of potential infective folliculitis. By day

APA, Harvard, Vancouver, ISO, and other styles

31

Volkers, A., L. Wieske, K. van Dam, et al. "DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study." Journal of Crohn's and Colitis 16, Supplement_1 (2022): i079. http://dx.doi.org/10.1093/ecco-jcc/jjab232.066.

Full text

Abstract:

Abstract Background The aim of this study was to investigate the effect of various immunosuppressants on the humoral immune responses after vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs). Methods The Target to B! SARS-CoV-2 study is a multicentre study, taking place in 7 Dutch academic hospitals. Patients with the following IMIDs were recruited: Crohn’s disease (CD), ulcerative colitis (UC), auto-immune hepatitis, rheumatic (e.g. rheumatoid arthritis), neurological (e.g. multiple sclerosis) and dermatological IMIDs (e.g. atopic dermatitis). Patien

APA, Harvard, Vancouver, ISO, and other styles

32

Megías-Vericat, Juan Eduardo, Tomás Palanques-Pastor, Mireya Fernández-Sánchez, et al. "Systematic Review of Pharmacogenetics of Immunosuppressants in Heart Transplantation." Cardiogenetics 15, no. 2 (2025): 18. https://doi.org/10.3390/cardiogenetics15020018.

Full text

Abstract:

The standard immunosuppressive treatments in heart transplantation are calcineurin inhibitors, corticosteroids, and antimetabolite agents or inhibitors of the mammalian target of rapamycin. Pharmacogenetic studies show the impact on clinical course of genetic variability in genes that encode transporters, metabolizers, or molecular targets of immunosuppressants. The aim of this systematic review is to elucidate the role that pharmacogenetics of immunosuppressant drugs plays in clinical outcomes upon heart transplantation. PubMed, EMBASE, the Cochrane Central Register, and the Database of Abstr

APA, Harvard, Vancouver, ISO, and other styles

33

Maeda, Mikiko, Hideki Shimomura, Sachi Tokunaga, Naoko Taniguchi, Tomoko Lee, and Yasuhiro Takeshima. "Clinical Characteristics and Treatment of Juvenile Myasthenia Gravis—A Single-Center Experience." Children 11, no. 5 (2024): 572. http://dx.doi.org/10.3390/children11050572.

Full text

Abstract:

Juvenile myasthenia gravis (MG) is a rare autoimmune neuromuscular disease, often treated with anticholinesterases, corticosteroids, and immunosuppressants. However, optimal treatment durations remain unclear. This study investigated the clinical characteristics and treatment of juvenile MG, including medication duration. The administration period for all drugs, immunosuppressants, and prednisolone at doses greater than 0.35 mg/kg daily was extracted retrospectively from medical records. Nineteen participants (8 boys, 11 girls) aged 8 months to 14 years (median, 2.5 years) at onset were identi

APA, Harvard, Vancouver, ISO, and other styles

34

Li, Mingxia, Fangfang Ge, Rongjing Guo, et al. "Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis." Therapeutic Advances in Neurological Disorders 12 (January 2019): 175628641987652. http://dx.doi.org/10.1177/1756286419876521.

Full text

Abstract:

Background: The majority of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia gravis (GMG), usually within 2 years of disease onset. The aim of this meta-analysis was to evaluate the effect of early prednisolone and other immunosuppressants therapy on the generalization rate in OMG patients. Methods: We searched the CENTRAL, EMBASE, and MEDLINE databases via the Ovid SP database for all relevant publications on 16 July 2018. Results: Eight studies comprising a total of 547 participants were included in our meta-analysis. Compared with pyridostigmine treatment, pre

APA, Harvard, Vancouver, ISO, and other styles

35

Belső, Nóra. "New therapeutic strategies of lichen ruber planus." Bőrgyógyászati és Venerológiai Szemle 97, no. 5 (2021): 278–82. http://dx.doi.org/10.7188/bvsz.2021.97.5.7.

Full text

Abstract:

Lichen ruber planus/lichen planus (LP), is a chronic immune-mediated inflammatory disease that affects the skin, oral mucosa, genital mucosa, scalp and nails. Planar, purple, polygonal, pruritic, papules and plaques appear on the flexor surfaces of the wrists, forearms and legs. Mucosal lesions are often lacy, reticular, white lines known as Wickham striae. Topical corticosteroids are the first-line therapy for all forms of LP, for severe, widespread LP systemic corticosteroids, acitretine, oral immunosuppressants or narrowband UVB therapy should be considered. Cutaneous LP may resolve spontan

APA, Harvard, Vancouver, ISO, and other styles

36

Ichimura, Takenori, Miwa Hinata, Daisuke Ichikura, and Shinya Suzuki. "Effectiveness of corticosteroids on immune checkpoint inhibitor-induced interstitial pneumonia among patients with a history of interstitial pneumonia: A case series." SAGE Open Medical Case Reports 9 (January 2021): 2050313X2110313. http://dx.doi.org/10.1177/2050313x211031313.

Full text

Abstract:

There are few reports on the effectiveness of corticosteroids for immune checkpoint inhibitor-induced interstitial pneumonia in patients with a history of interstitial pneumonia. We report on 10 non-small cell lung cancer patients with a history of interstitial pneumonia who experienced immune checkpoint inhibitor-induced interstitial pneumonia. The immune checkpoint inhibitor-induced interstitial pneumonia lasted for a median duration of 41.5 days (range = 22–127 days). Eight of the ten patients responded to corticosteroid monotherapy; one patient responded to corticosteroids and the immunosu

APA, Harvard, Vancouver, ISO, and other styles

37

Ashton, Rosalind, and Hiva Fassihi. "Pediatric Autoimmune Bullous Disease: A Literature Review and Update on Management." Pediatrics In Review 43, no. 6 (2022): 309–21. http://dx.doi.org/10.1542/pir.2021-005125.

Full text

Abstract:

Pediatric autoimmune bullous disease is a rare group of blistering skin disorders in children that result from autoimmunity against intercellular and basement membrane antigens in the skin and mucous membranes. Most pediatric cases are treated with oral corticosteroids or longer-term immunosuppressants such as azathioprine or mycophenolate mofetil. Immunomodulating drugs such as rituximab are increasingly being considered as options for refractory disease.

APA, Harvard, Vancouver, ISO, and other styles

38

Šurbatović, Maja, Goran Rakić, and Jasna Jevđić. "Corticosteroid use in critically ill patients." Galenika Medical Journal 2, no. 7 (2023): 27–33. http://dx.doi.org/10.5937/galmed2307027s.

Full text

Abstract:

The use of corticosteroids as immunosuppressants in critically ill patients is a very complex issue. These potent immunomodulators can be used in the treatment of critically ill patients with severe community-acquired pneumonia (SCAP) and/or septic shock. Local and systemic inflammatory responses are increased in SCAP, thus impairing gas exchange. Also, persistent inflammatory response is associated with higher mortality in patients with COVID-19 and non-COVID-19-related ARDS. However, the risk of administering systemic steroids (methylprednisolone, Dexamethasone, hydrocortisone, etc.) to non-

APA, Harvard, Vancouver, ISO, and other styles

39

Tomizawa, Minoru, Fuminobu Shinozaki, Rumiko Hasegawa, et al. "Comparison of Laboratory Data of Acute Cholangitis Patients Treated with or without Immunosuppressive Drugs." ISRN Gastroenterology 2014 (March 10, 2014): 1–5. http://dx.doi.org/10.1155/2014/619628.

Full text

Abstract:

Objective. Symptoms and laboratory data between acute cholangitis (AC) patients treated with and AC patients treated without immunosuppressive drugs (corticosteroids or methotrexate) were compared to identify factors that can be meaningful to the diagnosis of AC. Methods. The Wilcoxon signed-rank test was used for comparison of baseline variables between the patients with AC treated with immunosuppressive drugs and those without it. The chi-squared test was used in the analysis of the symptoms. Results. In total, 69 patients with AC were enrolled. Fifteen patients were treated with immunosuppr

APA, Harvard, Vancouver, ISO, and other styles

40

Tambunan, Laura, K. Ritarwan, and K. P. Surbakti. "Neuromyelitis Optica Spectrum Disorder: A Case Report of Effective Combination Immunosuppressant, Corticosteroids, and Therapeutic Plasma Exchange." Open Access Macedonian Journal of Medical Sciences 7, no. 20 (2019): 3433–36. http://dx.doi.org/10.3889/oamjms.2019.439.

Full text

Abstract:

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes severe demyelination, especially in the optic nerve and spinal cord with typical clinical manifestations of acute optic neuritis and transverse myelitis. The symptoms can occur simultaneously or separated by a variable period. NMOSD is associated with serum aquaporin antibodies 4 immunoglobulin G (AQP4-IgG). CASE PRESENTATION: We report a case of a 22-year-old male with complaints of weakness of all four limbs, impaired vision, urinary incontinence, and dyspnea. The Expanded Disability Status

APA, Harvard, Vancouver, ISO, and other styles

41

Visuddho, Nabil Alfin Juhri, Ludy Diana Wiradhika, and Reny I’tishom. "Microsphere as a novel strategy for the long-term use of corticosteroids in asthma patients during the COVID-19 Pandemic." World Journal of Advanced Research and Reviews 13, no. 1 (2022): 468–72. http://dx.doi.org/10.30574/wjarr.2022.13.1.0020.

Full text

Abstract:

The use of corticosteroids during the (Coronavirus Disease 2019) COVID-19 has become a new concern. Corticosteroids are the main therapy in asthmatic patients with anti-inflammatory and immunosuppressant effects. Patients with the need for long-term use of corticosteroids, such as asthma patients, are aware of the risk from infection obtained by the side effect of long-term corticosteroid use. A Recent study has innovated a new drug delivery agent, called Microsphere that can specify the targeted therapy. This new therapy may potentially increase the treatment efficacy with the lesser side eff

APA, Harvard, Vancouver, ISO, and other styles

42

Visuddho, Alfin Juhri Nabil, Diana Wiradhika Ludy, and I'tishom Reny. "Microsphere as a novel strategy for the long-term use of corticosteroids in asthma patients during the COVID-19 Pandemic." World Journal of Advanced Research and Reviews 13, no. 1 (2022): 468–72. https://doi.org/10.5281/zenodo.5896093.

Full text

Abstract:

The use of corticosteroids during the (Coronavirus Disease 2019) COVID-19 has become a new concern. Corticosteroids are the main therapy in asthmatic patients with anti-inflammatory and immunosuppressant effects. Patients with the need for long-term use of corticosteroids, such as asthma patients, are aware of the risk from infection obtained by the side effect of long-term corticosteroid use. A Recent study has innovated a new drug delivery agent, called Microsphere that can specify the targeted therapy. This new therapy may potentially increase the treatment efficacy with the lesser side eff

APA, Harvard, Vancouver, ISO, and other styles

43

Yamazaki, Hayato, Ryoko Sakai, Ryuji Koike, et al. "Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study." Journal of Rheumatology 42, no. 4 (2015): 614–22. http://dx.doi.org/10.3899/jrheum.140778.

Full text

Abstract:

Objective.Pulmonary infections (PI) are leading causes of death in patients with connective tissue diseases (CTD). The PREVENT study (Pulmonary infections in patients REceiving immunosuppressiVE treatmeNT for CTD) assessed risk of PI in patients with active CTD in the contemporary era of advanced immunosuppressive therapy.Methods.In patients who started corticosteroids (n = 763), conventional immunosuppressants or biologics for active CTD were enrolled. Clinical and laboratory data, usage of drugs, and occurrence of PI were collected for 12 months. Baseline risk factors were investigated using

APA, Harvard, Vancouver, ISO, and other styles

44

Elsayed, Eiman Hamza Ahmed, and Rabab Elsayed Ali Hassan Khater. "Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids." American Journal of Life Science and Innovation 3, no. 1 (2024): 61–68. http://dx.doi.org/10.54536/ajlsi.v3i1.2696.

Full text

Abstract:

Eczema, or atopic dermatitis, is a common, non-communicable, immune-mediated, inflammatory skin illness mainly affecting children. It is a chronic condition. It causes mental health problems like anxiety, sadness, anxiety, depression, hyperactivity, and obesity. It is the first skin ailment and the fifteenth non-fatal disease. The purpose of the present research study was to evaluate the Safety and Effectiveness of biological treatment for atopic dermatitis using monoclonal antibodies against non-biological treatment, including antibiotics, immunosuppressants, demards, histamine antagonists an

APA, Harvard, Vancouver, ISO, and other styles

45

"Corticosteroids/immunosuppressants." Reactions Weekly 1910, no. 1 (2022): 152. http://dx.doi.org/10.1007/s40278-022-16987-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Corticosteroids/immunosuppressants." Reactions Weekly 1838, no. 1 (2021): 160. http://dx.doi.org/10.1007/s40278-021-89479-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Immunosuppressants/corticosteroids." Reactions Weekly 2027, no. 1 (2024): 235. http://dx.doi.org/10.1007/s40278-024-67424-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Corticosteroids/immunosuppressants." Reactions Weekly 1692, no. 1 (2018): 114. http://dx.doi.org/10.1007/s40278-018-42642-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Corticosteroids/immunosuppressants." Reactions Weekly 1575, no. 1 (2015): 79. http://dx.doi.org/10.1007/s40278-015-10020-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Corticosteroids/immunosuppressants." Reactions Weekly 1726, no. 1 (2018): 137. http://dx.doi.org/10.1007/s40278-018-53776-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!